Purpose

This study is being conducted to determine if losartan, an angiotensin receptor blocker (ARB), is safe and effective in the treatment of posttraumatic stress disorder (PTSD) symptoms. The study is also intended to determine if certain genetic markers are useful in predicting PTSD symptom reduction with losartan. Approximately 160 subjects with chronic PTSD ages 18-65 will participate in this study across five sites. Subjects will be assigned by chance to take either flexibly dosed losartan (up to a maximum dosage of 100 mg) or placebo (which resembles the study drug but has no active ingredients), once a day for 10 weeks. Furthermore, it is hypothesized that CC homozygotes for rs4311 SNP in the ACE gene will have a superior response to losartan on PTSD symptoms compared to T carriers.

Condition

Eligibility

Eligible Ages
Between 18 Years and 70 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Subject must be a man or woman between 18 and 70 years of age, inclusive.
  2. Subjects must have a primary DSM-5 diagnosis of Posttraumatic Stress Disorder.
  3. Subjects must have a Clinical Administered PTSD Scale for PTSD (CAPS-5) ≥ 25 persistent at Screening for at least 3 months duration.
  4. Subject must be willing and able to adhere to the prohibitions and restrictions specified in this protocol.
  5. Subject must be willing and able to fill out self-administered questionnaires.
  6. Subject must be able to be compliant with self-administration of medication.
  7. Subject must be able to swallow the study medication whole with aid of water.
  8. Subject must sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.

Exclusion Criteria

  1. Subjects who have current or imminent risk of suicide as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) at each study visit.
  2. Subject with active psychosis.
  3. Subject has a history of moderate or severe drug or alcohol use disorder according to DSM-5 criteria within 3 months before screening.
  4. Subject has a history of allergy to losartan or other angiotensin receptor blockers (ARBs).
  5. Subject has a medical illness likely to result in imminent hospitalization or for which treatments are contraindicated based on lab results, medical history and physical exam.
  6. Subject has serious cognitive impairment felt likely to interfere with the ability to participate meaningfully in the study. Participants with mild to moderate traumatic brain injury (TBI) will not be excluded from the study. Only those who evidence significant cognitive impairment at Screening (as evidenced by confusion, inability to track discussion or answer questions, or other clear and significant indicators of cognitive impairment) will be excluded.
  7. Concurrent ACE Inhibitors or Angiotensin Receptor Blockers or Prazosin; patients on other antihypertensives may be enrolled if, after consultation with their prescribing physician, it is determined that the addition of losartan would not be contraindicated.
  8. Concurrent antidepressants or antipsychotics. Subjects, who have elected, in consultation with their health care provider, to discontinue any antidepressants or antipsychotics, must be off the medications for a minimum of 2 weeks prior to study randomization. Stable bedtime doses of sleep agents (e.g., trazodone ≤ 200mg; eszopiclone; zolpidem; lorazepam) will be allowed as long as the dose has been stable for at least 2 weeks prior to study randomization. Benzodiazepines taken for other than sleep are not permitted.
  9. Subject is a woman who is pregnant, or breast-feeding, or planning to become pregnant.
  10. Subject is unable to comply with the study-specific requirements
  11. Subjects with abnormal liver, renal or EKG findings as determined by physician.
  12. Subject exhibits clinically-significant hypertension as determined by medical evaluation and/or BP > 190/100.
  13. Systolic Blood Pressure (SBP) < 90mmHg.
  14. Liver function Tests (LFT's) > 2 times the upper limit of normal.
  15. Patients with Chronic Kidney Disease 4, as determined by history, baseline labs (including eGFR < 45ml/minute) and evaluation by a physician will be excluded

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Losartan
Losartan flexibly dosed from 25-100 mg per day over 10 weeks
  • Drug: losartan
    Angiotensin receptor blocker (ARB)
    Other names:
    • Cozaar
Placebo Comparator
Placebo
Placebo flexibly dosed from 25-100 mg per day over 10 weeks
  • Drug: Placebo
    Placebo

Recruiting Locations

Massachusetts General Hospital
Boston, Massachusetts 02114
Contact:
Emma R Toner, BA
617-726-1570
ertoner@mgh.harvard.edu

More Details

NCT ID
NCT02709018
Status
Recruiting
Sponsor
University of California, San Diego

Study Contact

Murray B Stein, MD, MPH
858-534-6451
mstein@ucsd.edu

Detailed Description

There are limited current treatments available for PTSD, and the only FDA-approved medications are SSRIs, which were empirically found to be somewhat helpful. Losartan provides a potentially important and exciting development in that it is readily available, safe, inexpensive (available as a generic drug), and has a neurobiological mechanism based on recent exciting discoveries, as outlined below. This proposal is designed to test, in a multisite RCT, this novel, mechanistically-determined, safe and well-tolerated, potentially powerful treatment for PTSD symptoms.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.